% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gven:286719,
      author       = {D. C. Güven$^*$ and M. S. Thong$^*$ and V. Arndt$^*$},
      title        = {{S}urvivorship outcomes in patients treated with immune
                      checkpoint inhibitors: a scoping review.},
      journal      = {Journal of cancer survivorship},
      volume       = {19},
      issn         = {1932-2259},
      address      = {New York, NY [u.a.]},
      publisher    = {Springer},
      reportid     = {DKFZ-2024-00059},
      pages        = {806–845},
      year         = {2025},
      note         = {EA:C071#EA:C070#LA:C071#LA:C070# / Volume 19, pages
                      806–845, (2025)},
      abstract     = {Immune checkpoint inhibitors (ICIs) have become a central
                      part of cancer care. However, the survivorship outcomes in
                      patients treated with ICIs are understudied. Therefore, we
                      conducted a scoping review to evaluate the current status of
                      the field and to establish research gaps regarding
                      survivorship outcomes with ICIs in real-life cohorts.We used
                      the Web of Science, PubMed, and Embase databases to
                      systematically filter published studies with real-life
                      cohorts from January 1, 2010, until October 19, 2022.
                      Studies evaluating at least one survivorship outcome in
                      ICI-treated patients were included.A total of 39 papers were
                      included. Quality of life (QoL) (n = 23), toxicity burden (n
                      = 16), and psychosocial issues (n = 9) were the most
                      frequently evaluated survivorship outcomes. Anti-PD-1/PD-L1
                      monotherapy and a response to treatment were associated with
                      better QoL. In addition, the ICIs were associated with grade
                      3 or higher immune-related adverse events (irAEs) in
                      $10-15\%$ and late/long-term irAEs in $20-30\%$ of the
                      survivors. Regarding psychosocial problems, over $30\%$ of
                      survivors showed evidence of anxiety and depression, and
                      $30-40\%$ of survivors reported neurocognitive
                      impairments.The survivors treated with ICIs have impairments
                      in most survivorship domains. Further research is needed to
                      gather data on the understudied survivorship outcomes like
                      late and long-term effects, fertility, financial toxicity,
                      and return to work in survivors treated with ICIs.Available
                      evidence demonstrates that a significant portion of
                      survivors treated with ICIs have a significant toxicity
                      burden, lower QoL than the general population, and a high
                      rate of psychosocial problems.},
      subtyp        = {Review Article},
      keywords     = {Immune checkpoint inhibitor (Other) / Immune-related
                      adverse event (Other) / Immunotherapy (Other) / Quality of
                      life (Other) / Survivorship (Other)},
      cin          = {C071 / C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C071-20160331 / I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38175366},
      doi          = {10.1007/s11764-023-01507-w},
      url          = {https://inrepo02.dkfz.de/record/286719},
}